BNL-101
/ Bionaut
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 23, 2021
FDA Grants Bionaut Labs Orphan Drug Designation to BNL-101 for the Treatment of Malignant Gliomas in Pediatric and Adult Patients
(PRNewswire)
- “Bionaut Labs…announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for BNL-101 for the local treatment of all malignant gliomas including diffuse intrinsic pontine glioma in pediatric and adult patients.”
Orphan drug • Glioma • Oncology
1 to 1
Of
1
Go to page
1